Skip to main content
OpenTrials
Completed

NCT Number: NCT02557334

Effects of Freeze Dried Strawberry Powder Supplementation on Vascular Function and Blood Markers of Cardiovascular Risk

The purpose of this study is to evaluate the effects of freeze dried strawberry powder on LDL cholesterol, central and peripheral blood pressure, indices of arterial stiffness, and other lipid and lipoprotein concentrations. The investigators hypothesize that the bioactive compounds in freeze dried strawberry powder may elicit beneficial effects on LDL cholesterol, as well as blood pressure and arterial health.

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Penn State CRC

University Park, Pennsylvania, 16803, United States

About this study

The proposed study design is a 3-period randomized crossover dose-response study to evaluate the effect of freeze dried strawberry powder supplementation on LDL-C and vascular health. Research participants will be overweight or obese (BMI 25-39 kg/m^2) but otherwise healthy adults with moderately elevated LDL-C (>116 mg/dL or >3.0mmol/L), blood pressure <160/100 mmHg, total cholesterol below 273 mg/dL for men and below 284 mg/dL for women, and triglycerides below 350 mg/dL. Subjects will be randomly assigned to three supplementation periods: 1) low dose freeze dried strawberry powder (13 g/d); 2) high dose freeze dried strawberry powder (40 g/d); and 3) a placebo powder. Each powder will be provided for 4-6 weeks, separated by a 2-week washout period between treatment periods. Baseline and endpoint testing will include blood collection and vascular testing.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women 35-65 years of age
  • BMI ≥ 25 and ≤ 39 kg/m^2
  • LDL-C > 116 mg/dL
  • Total Cholesterol below 273 mg/dL for men and below 284 mg/dL for women
  • Triglycerides below 350 mg/d
  • Non-smokers
  • Blood pressure < 160/100 mmHg

Exclusion criteria

  • History of acute or chronic inflammatory conditions or heart disease, kidney disease, liver disease, autoimmune disorders, or thyroid disease (unless controlled by medication and blood results within the previous 6 months are provided)
  • History of diabetes mellitus (and/or a fasting glucose > 126 mg/dL at screening)
  • Stage II hypertension (blood pressure ≥ 160/100 mmHg)
  • Lactation, pregnancy, or desire to become pregnant during the study
  • Unwillingness to discontinue nutritional supplements, herbs, or vitamins, unless approved by investigator
  • Use of medications/supplements for elevated lipids, blood pressure, or glucose
  • Chronic use of non-steroidal anti-inflammatory or immunosuppressant medication
  • Conditions requiring the use of steroids
  • Unwillingness to refrain from blood donation prior to and during the study
  • Any medical condition or abnormal laboratory value that is judged clinically significant by an investigator
  • Allergy or sensitivity to strawberries or any ingredient in the study powders

Treatment and study plan

Low Dose Strawberry Powder

Dietary Supplement

40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder

High Dose Strawberry Powder

Dietary Supplement

40 g freeze dried strawberry powder

Placebo Powder

Dietary Supplement

40 g color and taste matched placebo powder

Primary outcomes

  1. LDL-C

    Time frame: Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage

    LDL-C values calculated using the Friedewald equation

Secondary outcomes

  1. Central Blood Pressure

    Time frame: Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage

    Aortic (central) blood pressure measured using the SphygmoCor System

  2. Peripheral Blood Pressure

    Time frame: Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage

    Peripheral blood pressure measured using the SphygmoCor System

  3. Augmentation Index

    Time frame: Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage

    Augmentation index measured using the SphygmoCor System

  4. Pulse Wave Velocity

    Time frame: Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage

    Pulse wave velocity measured using the SphygmoCor System

  5. Total Cholesterol

    Time frame: Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage

    Total cholesterol values determined by enzymatic procedures

  6. Triglycerides

    Time frame: Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage

    Triglyceride values determined using enzymatic procedures

  7. HDL-C

    Time frame: Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage

    HDL-C will be estimated according to the modified heparin-manganese procedure

  8. Oxidized LDL (oxLDL)

    Time frame: Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage

    Plasma concentrations of oxLDL will be measured using ELISA kits

  9. Malondialdehyde (MDA)

    Time frame: Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage

    MDA will be measured using the thiobarbituric acid reactive substances (TBARS) assay

  10. High Sensitivity C Reactive Protein (hs-CRP)

    Time frame: Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage

    hs-CRP will be measured by latex-enhanced immunonephelometry

Sponsors and collaborators

Lead sponsor

Penn State University

Other

Collaborators

  • California Strawberry Commission

Registry information

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Sep 23, 2015
Registry last updated
Aug 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.